Should a Group Practice Buy a Standalone AI Scribe or an EHR With AI Built In?

Short answer: a standalone AI scribe (Mentalyc, Upheal, Blueprint, and similar tools) adds a second vendor that touches every session's audio and content, on top of whatever EHR already holds the chart. An EHR with AI documentation built in keeps the note, the record it's attached to, and the claim it generates in one system. The standalone route can still make sense, but a practice should know exactly what it's trading before choosing it.

This draws on Oasys's ongoing conversations with practice owners weighing exactly this decision, and Oasys's own seat at the infrastructure layer of practices running AI documentation daily. The question comes up constantly because it looks like a feature comparison and is actually a data-flow decision: once session audio leaves a practice's primary system, a second business associate, a second retention policy, and a second point of failure all come with it.

Below is what actually separates the two approaches, not on transcription quality (most tools in both categories are competent at that now), but on what happens to the note before and after it's written.

What changes when the scribe is a separate vendor

A standalone scribe is its own HIPAA business associate, with its own BAA, its own audio and transcript retention policy, and its own data-handling practices, independent of whatever the EHR does. A practice evaluating one has to ask the same due-diligence questions twice: once for the scribe, once for the EHR, because a strong answer from one does not cover the other.

Oasys treats every vendor that touches session audio or a drafted note as a HIPAA business associate by default, which is the same standard a standalone scribe should be held to. The difference is that with AI documentation built into the EHR, there is exactly one vendor relationship to evaluate instead of two.

The copy-paste problem

The practical friction shows up after the note is drafted, not during the session. A standalone scribe produces a note in its own interface, and someone, usually the clinician, has to get that content into the actual chart. Practices running a separate tool for anything, assessments, analytics, a second scribe, describe the same failure mode regardless of what the tool is: "it doesn't integrate, and so they have to pull the [content] and feed that back into the EHR, and some of them aren't even doing that."

Oasys writes the AI-drafted note directly into the chart it belongs to, so there is no copy-paste step and no version of the note that exists only in a second system. Other platforms may be built differently, and a scribe that is not the EHR itself almost always requires a manual transfer step somewhere.

The billing disconnect

A note is not just a clinical record, it is also what a claim gets coded from. A standalone scribe that is not connected to billing produces a good note and stops there; the CPT code, the diagnosis code, and the claim still have to be generated somewhere else, usually by hand, from a note that now lives in two places.

Oasys generates the CPT-coded claim directly from the signed note, so the same AI-assisted documentation that saves drafting time also feeds billing without a second data-entry step. A standalone scribe cannot do this by definition, because it does not hold the billing relationship, only the note.

Where a standalone scribe can still make sense

The honest case for a standalone tool: a practice happy with its current EHR's non-AI workflow, not wanting to migrate systems just to get AI documentation, or needing a scribe tuned to a specific specialty (psychiatry-specific tools, for instance) that a general EHR's built-in AI does not match closely. That is a real tradeoff, not a reason to dismiss the standalone option outright, it is a reason to weigh the integration cost against the specific gap a standalone tool closes.

A solo practice testing whether AI documentation helps at all, before committing to switching EHRs, is also a reasonable place to start with a standalone tool. The calculus changes at group-practice scale, where the copy-paste and billing gaps multiply across every clinician, every week.

What to ask before you commit either way

Is the AI tool, standalone or built in, a named HIPAA business associate with its own BAA, and has a practice actually seen it?

Does the drafted note land in the chart automatically, or does a clinician manually move it there?

Does the note connect to a claim, or does someone code and submit separately from what the AI drafted?

If a practice already likes its EHR and just wants AI added, does the EHR have a credible native roadmap, or is a standalone tool actually the only real option today?

Oasys answers the second and third questions by design, since the note and the claim are generated from the same signed record rather than assembled from separate tools.

How Oasys handles it

Oasys's AI documentation is native, not a connected third-party product: the drafted note lands directly in the chart, audio is not stored beyond the live transcription window, consent is tracked per client, and the signed note generates the CPT-coded claim directly. A practice evaluating Oasys is evaluating one vendor relationship, not a scribe plus an EHR plus the connection between them.